Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-012-968 RSV Challenge Study
NCT04690335Phase 2Completed
- Sponsor
- Meissa Vaccines
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MV-012-968 in respiratory syncytial virus infection (RSV), sponsored by Meissa Vaccines. Started Dec 2020; status: completed.
02
Drugs
MV-012-968
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04690335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690335.